Zura Bio Limited (NASDAQ: ZURA) Stock Competitors & Peer Comparison
See ZURA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZURA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZURA | $1.24 | -69.68% | 119.4M | -1.14 | -$1.09 | N/A |
| VRTX | $550.87 | +0.69% | 139.6B | 28.95 | $19.03 | N/A |
| MRNA | $269.00 | +5.83% | 107.4B | -33.00 | -$8.15 | N/A |
| REGN | $919.96 | +1.73% | 95.2B | 20.17 | $45.63 | +0.41% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $962.27 | +3.78% | 59.8B | 34.71 | $27.73 | N/A |
| ONC | $417.33 | +2.55% | 44.6B | 73.48 | $5.68 | N/A |
| RVMDW | $10.77 | +8.79% | 43.2B | -1.22 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $200.15 | +4.09% | 43B | -22.72 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ZURA vs VRTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, VRTX has a market cap of 139.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while VRTX trades at $550.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas VRTX's P/E ratio is 28.95. In terms of profitability, ZURA's ROE is -0.54%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, ZURA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ZURA vs MRNA Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MRNA has a market cap of 107.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MRNA trades at $269.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MRNA's P/E ratio is -33.00. In terms of profitability, ZURA's ROE is -0.54%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, ZURA is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ZURA vs REGN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, REGN has a market cap of 95.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while REGN trades at $919.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas REGN's P/E ratio is 20.17. In terms of profitability, ZURA's ROE is -0.54%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ZURA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ZURA vs VRNA Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ZURA's ROE is -0.54%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ZURA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ZURA vs ARGX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ARGX has a market cap of 59.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ARGX trades at $962.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ARGX's P/E ratio is 34.71. In terms of profitability, ZURA's ROE is -0.54%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, ZURA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
ZURA vs ONC Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ONC has a market cap of 44.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ONC trades at $417.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ONC's P/E ratio is 73.48. In terms of profitability, ZURA's ROE is -0.54%, compared to ONC's ROE of +0.18%. Regarding short-term risk, ZURA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ONC's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ZURA vs RVMDW Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RVMDW has a market cap of 43.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RVMDW trades at $10.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RVMDW's P/E ratio is -1.22. In terms of profitability, ZURA's ROE is -0.54%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, ZURA is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RVMDW's competition here
Seagen Inc. (NASDAQ: SGEN)
ZURA vs SGEN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ZURA's ROE is -0.54%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ZURA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ZURA vs RVMD Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RVMD has a market cap of 43B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RVMD trades at $200.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RVMD's P/E ratio is -22.72. In terms of profitability, ZURA's ROE is -0.54%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, ZURA is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RVMD's competition here
Genmab A/S (NASDAQ: GMAB)
ZURA vs GMAB Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, GMAB has a market cap of 34.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while GMAB trades at $55.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas GMAB's P/E ratio is 42.05. In terms of profitability, ZURA's ROE is -0.54%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ZURA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ZURA vs ROIV Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ROIV has a market cap of 29.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ROIV trades at $40.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ROIV's P/E ratio is -38.67. In terms of profitability, ZURA's ROE is -0.54%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ZURA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
ZURA vs INSM Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, INSM has a market cap of 25.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while INSM trades at $116.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas INSM's P/E ratio is -41.16. In terms of profitability, ZURA's ROE is -0.54%, compared to INSM's ROE of -0.83%. Regarding short-term risk, ZURA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ZURA vs UTHR Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, UTHR has a market cap of 25B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while UTHR trades at $582.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas UTHR's P/E ratio is 20.85. In terms of profitability, ZURA's ROE is -0.54%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ZURA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
ZURA vs INCY Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, INCY has a market cap of 24.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while INCY trades at $121.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas INCY's P/E ratio is 16.38. In terms of profitability, ZURA's ROE is -0.54%, compared to INCY's ROE of +0.07%. Regarding short-term risk, ZURA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ZURA vs BNTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while BNTX trades at $87.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas BNTX's P/E ratio is -11.35. In terms of profitability, ZURA's ROE is -0.54%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, ZURA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ZURA vs ALNY Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ALNY has a market cap of 21B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ALNY trades at $156.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ALNY's P/E ratio is 7.91. In terms of profitability, ZURA's ROE is -0.54%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, ZURA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ZURA vs BGNE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ZURA's ROE is -0.54%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, ZURA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ZURA vs DNA-WT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ZURA's ROE is -0.54%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ZURA is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ZURA vs EXEL Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, EXEL has a market cap of 18B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while EXEL trades at $71.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas EXEL's P/E ratio is 20.50. In terms of profitability, ZURA's ROE is -0.54%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, ZURA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ZURA vs ASND Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ASND has a market cap of 17.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ASND trades at $259.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ASND's P/E ratio is -107.37. In terms of profitability, ZURA's ROE is -0.54%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ZURA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ZURA vs NBIX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, NBIX has a market cap of 17.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while NBIX trades at $168.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas NBIX's P/E ratio is 24.40. In terms of profitability, ZURA's ROE is -0.54%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, ZURA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ZURA vs JAZZ Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while JAZZ trades at $243.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas JAZZ's P/E ratio is 9.08. In terms of profitability, ZURA's ROE is -0.54%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, ZURA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ZURA vs BBIO Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, BBIO has a market cap of 15.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while BBIO trades at $77.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas BBIO's P/E ratio is -25.63. In terms of profitability, ZURA's ROE is -0.54%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, ZURA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ZURA vs SMMT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while SMMT trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas SMMT's P/E ratio is -15.93. In terms of profitability, ZURA's ROE is -0.54%, compared to SMMT's ROE of -1.59%. Regarding short-term risk, ZURA is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ZURA vs KRTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ZURA's ROE is -0.54%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ZURA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check KRTX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ZURA vs KYMR Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, KYMR has a market cap of 11.9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while KYMR trades at $138.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas KYMR's P/E ratio is -38.37. In terms of profitability, ZURA's ROE is -0.54%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ZURA is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check KYMR's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ZURA vs HALO Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, HALO has a market cap of 11.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while HALO trades at $102.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas HALO's P/E ratio is 19.21. In terms of profitability, ZURA's ROE is -0.54%, compared to HALO's ROE of +5.44%. Regarding short-term risk, ZURA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ZURA vs TECH Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TECH trades at $72.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TECH's P/E ratio is 37.53. In terms of profitability, ZURA's ROE is -0.54%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ZURA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ZURA vs RNAM Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ZURA's ROE is -0.54%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ZURA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ZURA vs BMRN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while BMRN trades at $57.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas BMRN's P/E ratio is 27.49. In terms of profitability, ZURA's ROE is -0.54%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, ZURA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check BMRN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ZURA vs PCVX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, PCVX has a market cap of 10.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while PCVX trades at $67.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas PCVX's P/E ratio is -8.85. In terms of profitability, ZURA's ROE is -0.54%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, ZURA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ZURA vs SYRE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, SYRE has a market cap of 10.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while SYRE trades at $109.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas SYRE's P/E ratio is -55.92. In terms of profitability, ZURA's ROE is -0.54%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, ZURA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check SYRE's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ZURA vs MDGL Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MDGL has a market cap of 10B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MDGL trades at $432.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MDGL's P/E ratio is -33.84. In terms of profitability, ZURA's ROE is -0.54%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, ZURA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MDGL's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ZURA vs TGTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TGTX has a market cap of 9.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TGTX trades at $63.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TGTX's P/E ratio is 22.97. In terms of profitability, ZURA's ROE is -0.54%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ZURA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TGTX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ZURA vs RXDX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ZURA's ROE is -0.54%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ZURA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ZURA vs PRAX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, PRAX has a market cap of 9.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while PRAX trades at $332.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas PRAX's P/E ratio is -25.77. In terms of profitability, ZURA's ROE is -0.54%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ZURA is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ZURA vs NUVL Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ZURA's ROE is -0.54%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ZURA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ZURA vs CRNX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ZURA's ROE is -0.54%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ZURA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CRNX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ZURA vs KRYS Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while KRYS trades at $303.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas KRYS's P/E ratio is 37.98. In terms of profitability, ZURA's ROE is -0.54%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, ZURA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check KRYS's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ZURA vs TWST Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TWST has a market cap of 8.9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TWST trades at $135.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TWST's P/E ratio is -61.00. In terms of profitability, ZURA's ROE is -0.54%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ZURA is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TWST's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ZURA vs PTGX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while PTGX trades at $135.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas PTGX's P/E ratio is 131.92. In terms of profitability, ZURA's ROE is -0.54%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, ZURA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ZURA vs IMGN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ZURA's ROE is -0.54%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ZURA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check IMGN's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ZURA vs APGE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas APGE's P/E ratio is -31.19. In terms of profitability, ZURA's ROE is -0.54%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ZURA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ZURA vs BPMC Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ZURA's ROE is -0.54%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ZURA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ZURA vs CERE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CERE's P/E ratio is -16.47. In terms of profitability, ZURA's ROE is -0.54%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ZURA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ZURA vs RYTM Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RYTM trades at $113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RYTM's P/E ratio is -36.63. In terms of profitability, ZURA's ROE is -0.54%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, ZURA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RYTM's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ZURA vs TXG Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TXG has a market cap of 7.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TXG trades at $65.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TXG's P/E ratio is -110.29. In terms of profitability, ZURA's ROE is -0.54%, compared to TXG's ROE of -0.08%. Regarding short-term risk, ZURA is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TXG's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ZURA vs CYTK Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CYTK trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CYTK's P/E ratio is -7.64. In terms of profitability, ZURA's ROE is -0.54%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, ZURA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
ZURA vs ABVX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ABVX trades at $87.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ABVX's P/E ratio is -14.29. In terms of profitability, ZURA's ROE is -0.54%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ZURA is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ABVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ZURA vs IBRX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while IBRX trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas IBRX's P/E ratio is -7.32. In terms of profitability, ZURA's ROE is -0.54%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ZURA is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ZURA vs MTSR Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ZURA's ROE is -0.54%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ZURA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MTSR's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ZURA vs IMVT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, IMVT has a market cap of 7.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while IMVT trades at $35.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas IMVT's P/E ratio is -12.48. In terms of profitability, ZURA's ROE is -0.54%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ZURA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check IMVT's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ZURA vs CAI Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CAI has a market cap of 7.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CAI trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CAI's P/E ratio is 71.86. In terms of profitability, ZURA's ROE is -0.54%, compared to CAI's ROE of +0.16%. Regarding short-term risk, ZURA is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CAI's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ZURA vs AXSM Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, AXSM has a market cap of 7.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while AXSM trades at $133.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas AXSM's P/E ratio is -35.01. In terms of profitability, ZURA's ROE is -0.54%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, ZURA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ZURA vs ARWR Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ARWR has a market cap of 7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ARWR trades at $49.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ARWR's P/E ratio is -21.88. In terms of profitability, ZURA's ROE is -0.54%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ZURA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ARWR's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ZURA vs ORKA Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ORKA has a market cap of 6.9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ORKA trades at $104.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ORKA's P/E ratio is -53.91. In terms of profitability, ZURA's ROE is -0.54%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ZURA is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ORKA's competition here
Merus N.V. (NASDAQ: MRUS)
ZURA vs MRUS Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ZURA's ROE is -0.54%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ZURA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MRUS's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ZURA vs KOD Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, KOD has a market cap of 6.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while KOD trades at $107.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas KOD's P/E ratio is -25.69. In terms of profitability, ZURA's ROE is -0.54%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ZURA is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check KOD's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ZURA vs ACLX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ZURA's ROE is -0.54%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ZURA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
ZURA vs CGON Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CGON trades at $74.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CGON's P/E ratio is -27.82. In terms of profitability, ZURA's ROE is -0.54%, compared to CGON's ROE of -0.19%. Regarding short-term risk, ZURA is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ZURA vs RETA Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RETA's P/E ratio is -66.29. In terms of profitability, ZURA's ROE is -0.54%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ZURA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ZURA vs BLTE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while BLTE trades at $157.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas BLTE's P/E ratio is -84.36. In terms of profitability, ZURA's ROE is -0.54%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ZURA is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ZURA vs LGND Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while LGND trades at $314.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas LGND's P/E ratio is 34.48. In terms of profitability, ZURA's ROE is -0.54%, compared to LGND's ROE of +0.05%. Regarding short-term risk, ZURA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ZURA vs SRRK Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while SRRK trades at $51.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas SRRK's P/E ratio is -14.95. In terms of profitability, ZURA's ROE is -0.54%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ZURA is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check SRRK's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ZURA vs CNTA Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ZURA's ROE is -0.54%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ZURA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CNTA's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ZURA vs TERN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TERN's P/E ratio is -51.41. In terms of profitability, ZURA's ROE is -0.54%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ZURA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TERN's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ZURA vs MIRM Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MIRM trades at $93.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MIRM's P/E ratio is -6.40. In terms of profitability, ZURA's ROE is -0.54%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, ZURA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
ZURA vs MANE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MANE has a market cap of 6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MANE trades at $143.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MANE's P/E ratio is -45.78. In terms of profitability, ZURA's ROE is -0.54%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ZURA is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MANE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ZURA vs COGT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while COGT trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas COGT's P/E ratio is -15.90. In terms of profitability, ZURA's ROE is -0.54%, compared to COGT's ROE of -0.71%. Regarding short-term risk, ZURA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check COGT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ZURA vs CDTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ZURA's ROE is -0.54%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ZURA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ZURA vs ABCM Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ZURA's ROE is -0.54%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ZURA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ZURA vs ISEE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ZURA's ROE is -0.54%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ZURA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
ZURA vs ERAS Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ERAS trades at $15.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ERAS's P/E ratio is -16.80. In terms of profitability, ZURA's ROE is -0.54%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ZURA is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ZURA vs PTCT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while PTCT trades at $65.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas PTCT's P/E ratio is -46.44. In terms of profitability, ZURA's ROE is -0.54%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, ZURA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ZURA vs APLS Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas APLS's P/E ratio is 38.35. In terms of profitability, ZURA's ROE is -0.54%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ZURA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check APLS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ZURA vs EWTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, EWTX has a market cap of 5.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while EWTX trades at $48.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas EWTX's P/E ratio is -26.35. In terms of profitability, ZURA's ROE is -0.54%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, ZURA is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check EWTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ZURA vs IONS Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, IONS has a market cap of 5.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while IONS trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas IONS's P/E ratio is -9.48. In terms of profitability, ZURA's ROE is -0.54%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ZURA is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check IONS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ZURA vs DNTH Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while DNTH trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas DNTH's P/E ratio is -21.68. In terms of profitability, ZURA's ROE is -0.54%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ZURA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ZURA vs TVTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TVTX trades at $51.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TVTX's P/E ratio is -114.71. In terms of profitability, ZURA's ROE is -0.54%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, ZURA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TVTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ZURA vs CRSP Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CRSP trades at $50.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CRSP's P/E ratio is -10.52. In terms of profitability, ZURA's ROE is -0.54%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, ZURA is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CRSP's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ZURA vs ADPT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ADPT has a market cap of 4.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ADPT trades at $30.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ADPT's P/E ratio is -73.77. In terms of profitability, ZURA's ROE is -0.54%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, ZURA is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ADPT's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ZURA vs DFTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while DFTX trades at $35.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas DFTX's P/E ratio is N/A. In terms of profitability, ZURA's ROE is -0.54%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ZURA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ZURA vs FOLD Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ZURA's ROE is -0.54%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ZURA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ZURA vs AKRO Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ZURA's ROE is -0.54%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ZURA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check AKRO's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ZURA vs LEGN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, LEGN has a market cap of 4.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while LEGN trades at $24.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas LEGN's P/E ratio is -35.75. In terms of profitability, ZURA's ROE is -0.54%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ZURA is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check LEGN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ZURA vs RLAY Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RLAY trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RLAY's P/E ratio is -12.99. In terms of profitability, ZURA's ROE is -0.54%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, ZURA is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RLAY's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ZURA vs ALPN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ZURA's ROE is -0.54%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ZURA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ALPN's competition here
Opthea Limited (NASDAQ: OPT)
ZURA vs OPT Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas OPT's P/E ratio is -1.52. In terms of profitability, ZURA's ROE is -0.54%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ZURA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ZURA vs PRTC Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ZURA's ROE is -0.54%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ZURA is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ZURA vs MRTX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ZURA's ROE is -0.54%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ZURA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check MRTX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ZURA vs ABCL Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ABCL has a market cap of 4.1B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ABCL trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ABCL's P/E ratio is -23.15. In terms of profitability, ZURA's ROE is -0.54%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ZURA is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ABCL's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ZURA vs XENE Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, XENE has a market cap of 3.9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while XENE trades at $40.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas XENE's P/E ratio is -8.59. In terms of profitability, ZURA's ROE is -0.54%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ZURA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check XENE's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ZURA vs CPRX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ZURA's ROE is -0.54%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ZURA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CPRX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ZURA vs TNGX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while TNGX trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas TNGX's P/E ratio is -27.40. In terms of profitability, ZURA's ROE is -0.54%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ZURA is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check TNGX's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ZURA vs AMLX Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while AMLX trades at $30.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas AMLX's P/E ratio is -20.16. In terms of profitability, ZURA's ROE is -0.54%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, ZURA is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check AMLX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ZURA vs ELVN Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while ELVN trades at $51.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas ELVN's P/E ratio is -30.87. In terms of profitability, ZURA's ROE is -0.54%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, ZURA is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ZURA vs RYZB Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ZURA's ROE is -0.54%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ZURA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ZURA vs CBAY Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ZURA's ROE is -0.54%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ZURA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check CBAY's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ZURA vs PBLS Comparison November 2026
Zura Bio Limited (NASDAQ: ZURA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZURA stands at 119.4M. In comparison, PBLS has a market cap of 3.7B. Regarding current trading prices, ZURA is priced at $1.24 on the NASDAQ, while PBLS trades at $30.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZURA currently has a P/E ratio of -1.14, whereas PBLS's P/E ratio is -3.19. In terms of profitability, ZURA's ROE is -0.54%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ZURA is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for ZURA.Check PBLS's competition here